European Biotech Acquisition Operating Income

As of the most recent data (December 2022), EBAC shows a operating income of $-2.8M. That compares with $-1.1M in the prior-year period — down 156.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, EBAC's operating income is now $-2.8M (was $-1.1M) — a 156.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether European Biotech Acquisition is outperforming or lagging.

Tracking EBAC's operating income over time shows whether European Biotech Acquisition is scaling, shrinking, or reshaping that part of the business. The current reading is $-2.8M That compares with $-1.1M in the prior-year period — down 156.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has European Biotech Acquisition's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-2.8M) with ownership activity and broader fundamentals.